Serum Cardiac Troponin-I is Superior to Troponin-T as a Marker for Left Ventricular Dysfunction in Clinically Stable Patients with End-Stage Renal Disease.
Serum troponin assays, widely used to detect acute cardiac ischemia, might be useful biomarkers to detect chronic cardiovascular disease (CVD). Cardiac-specific troponin-I (cTnI) and troponin-T (cTnT) generally detect myocardial necrosis equally well. In dialysis patients however, serum cTnT levels...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4523186?pdf=render |
id |
doaj-90e270afa0bf4b268b64551bfc8a73b8 |
---|---|
record_format |
Article |
spelling |
doaj-90e270afa0bf4b268b64551bfc8a73b82020-11-25T00:57:18ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01108e013424510.1371/journal.pone.0134245Serum Cardiac Troponin-I is Superior to Troponin-T as a Marker for Left Ventricular Dysfunction in Clinically Stable Patients with End-Stage Renal Disease.Maurits S BuitenMihály K de BieJoris I RotmansFriedo W DekkerMarjolijn van BurenTon J RabelinkChrista M CobbaertMartin J SchalijArnoud van der LaarseJ Wouter JukemaSerum troponin assays, widely used to detect acute cardiac ischemia, might be useful biomarkers to detect chronic cardiovascular disease (CVD). Cardiac-specific troponin-I (cTnI) and troponin-T (cTnT) generally detect myocardial necrosis equally well. In dialysis patients however, serum cTnT levels are often elevated, unlike cTnI levels. The present study aims to elucidate the associations of cTnI and cTnT with CVD in clinically stable dialysis patients.Troponin levels were measured using 5th generation hs-cTnT assays (Roche) and STAT hs-cTnI assays (Abbott) in a cohort of dialysis patients. Serum troponin levels were divided into tertiles with the lowest tertile as a reference value. Serum troponins were associated with indicators of CVD such as left ventricular mass index (LVMI), left ventricular ejection fraction (LVEF) and the presence of coronary artery disease (CAD). Associations were explored using regression analysis.We included 154 consecutive patients, 68±7 years old, 77% male, 70% hemodialysis. Median serum cTnT was 51ng/L (exceeding the 99th percentile of the healthy population in 98%) and median serum cTnI was 13ng/L (elevated in 20%). A high cTnI (T3) was significantly associated with a higher LVMI (Beta 31.60; p=0.001) and LVEF (Beta -4.78; p=0.005) after adjusting for confounders whereas a high serum cTnT was not. CAD was significantly associated with a high cTnT (OR 4.70 p=0.02) but not with a high cTnI. Unlike cTnI, cTnT was associated with residual renal function (Beta:-0.09; p=0.006).In the present cohort, serum cTnI levels showed a stronger association with LVMI and LVEF than cTnT. However, cTnT was significantly associated with CAD and residual renal function, unlike cTnI. Therefore, cTnI seems to be superior to cTnT as a marker of left ventricular dysfunction in asymptomatic dialysis patients, while cTnT might be better suited to detect CAD in these patients.http://europepmc.org/articles/PMC4523186?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Maurits S Buiten Mihály K de Bie Joris I Rotmans Friedo W Dekker Marjolijn van Buren Ton J Rabelink Christa M Cobbaert Martin J Schalij Arnoud van der Laarse J Wouter Jukema |
spellingShingle |
Maurits S Buiten Mihály K de Bie Joris I Rotmans Friedo W Dekker Marjolijn van Buren Ton J Rabelink Christa M Cobbaert Martin J Schalij Arnoud van der Laarse J Wouter Jukema Serum Cardiac Troponin-I is Superior to Troponin-T as a Marker for Left Ventricular Dysfunction in Clinically Stable Patients with End-Stage Renal Disease. PLoS ONE |
author_facet |
Maurits S Buiten Mihály K de Bie Joris I Rotmans Friedo W Dekker Marjolijn van Buren Ton J Rabelink Christa M Cobbaert Martin J Schalij Arnoud van der Laarse J Wouter Jukema |
author_sort |
Maurits S Buiten |
title |
Serum Cardiac Troponin-I is Superior to Troponin-T as a Marker for Left Ventricular Dysfunction in Clinically Stable Patients with End-Stage Renal Disease. |
title_short |
Serum Cardiac Troponin-I is Superior to Troponin-T as a Marker for Left Ventricular Dysfunction in Clinically Stable Patients with End-Stage Renal Disease. |
title_full |
Serum Cardiac Troponin-I is Superior to Troponin-T as a Marker for Left Ventricular Dysfunction in Clinically Stable Patients with End-Stage Renal Disease. |
title_fullStr |
Serum Cardiac Troponin-I is Superior to Troponin-T as a Marker for Left Ventricular Dysfunction in Clinically Stable Patients with End-Stage Renal Disease. |
title_full_unstemmed |
Serum Cardiac Troponin-I is Superior to Troponin-T as a Marker for Left Ventricular Dysfunction in Clinically Stable Patients with End-Stage Renal Disease. |
title_sort |
serum cardiac troponin-i is superior to troponin-t as a marker for left ventricular dysfunction in clinically stable patients with end-stage renal disease. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2015-01-01 |
description |
Serum troponin assays, widely used to detect acute cardiac ischemia, might be useful biomarkers to detect chronic cardiovascular disease (CVD). Cardiac-specific troponin-I (cTnI) and troponin-T (cTnT) generally detect myocardial necrosis equally well. In dialysis patients however, serum cTnT levels are often elevated, unlike cTnI levels. The present study aims to elucidate the associations of cTnI and cTnT with CVD in clinically stable dialysis patients.Troponin levels were measured using 5th generation hs-cTnT assays (Roche) and STAT hs-cTnI assays (Abbott) in a cohort of dialysis patients. Serum troponin levels were divided into tertiles with the lowest tertile as a reference value. Serum troponins were associated with indicators of CVD such as left ventricular mass index (LVMI), left ventricular ejection fraction (LVEF) and the presence of coronary artery disease (CAD). Associations were explored using regression analysis.We included 154 consecutive patients, 68±7 years old, 77% male, 70% hemodialysis. Median serum cTnT was 51ng/L (exceeding the 99th percentile of the healthy population in 98%) and median serum cTnI was 13ng/L (elevated in 20%). A high cTnI (T3) was significantly associated with a higher LVMI (Beta 31.60; p=0.001) and LVEF (Beta -4.78; p=0.005) after adjusting for confounders whereas a high serum cTnT was not. CAD was significantly associated with a high cTnT (OR 4.70 p=0.02) but not with a high cTnI. Unlike cTnI, cTnT was associated with residual renal function (Beta:-0.09; p=0.006).In the present cohort, serum cTnI levels showed a stronger association with LVMI and LVEF than cTnT. However, cTnT was significantly associated with CAD and residual renal function, unlike cTnI. Therefore, cTnI seems to be superior to cTnT as a marker of left ventricular dysfunction in asymptomatic dialysis patients, while cTnT might be better suited to detect CAD in these patients. |
url |
http://europepmc.org/articles/PMC4523186?pdf=render |
work_keys_str_mv |
AT mauritssbuiten serumcardiactroponiniissuperiortotroponintasamarkerforleftventriculardysfunctioninclinicallystablepatientswithendstagerenaldisease AT mihalykdebie serumcardiactroponiniissuperiortotroponintasamarkerforleftventriculardysfunctioninclinicallystablepatientswithendstagerenaldisease AT jorisirotmans serumcardiactroponiniissuperiortotroponintasamarkerforleftventriculardysfunctioninclinicallystablepatientswithendstagerenaldisease AT friedowdekker serumcardiactroponiniissuperiortotroponintasamarkerforleftventriculardysfunctioninclinicallystablepatientswithendstagerenaldisease AT marjolijnvanburen serumcardiactroponiniissuperiortotroponintasamarkerforleftventriculardysfunctioninclinicallystablepatientswithendstagerenaldisease AT tonjrabelink serumcardiactroponiniissuperiortotroponintasamarkerforleftventriculardysfunctioninclinicallystablepatientswithendstagerenaldisease AT christamcobbaert serumcardiactroponiniissuperiortotroponintasamarkerforleftventriculardysfunctioninclinicallystablepatientswithendstagerenaldisease AT martinjschalij serumcardiactroponiniissuperiortotroponintasamarkerforleftventriculardysfunctioninclinicallystablepatientswithendstagerenaldisease AT arnoudvanderlaarse serumcardiactroponiniissuperiortotroponintasamarkerforleftventriculardysfunctioninclinicallystablepatientswithendstagerenaldisease AT jwouterjukema serumcardiactroponiniissuperiortotroponintasamarkerforleftventriculardysfunctioninclinicallystablepatientswithendstagerenaldisease |
_version_ |
1725224788429897728 |